- Home
- TSHA vs GABC Comparison
TSHA vs GABC Comparison
Compare TSHA & GABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- GABC
- Stock Information
- Founded
- TSHA 2019
- GABC 1910
- Country
- TSHA United States
- GABC United States
- Employees
- TSHA N/A
- GABC N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- GABC Major Banks
- Sector
- TSHA Health Care
- GABC Finance
- Exchange
- TSHA Nasdaq
- GABC Nasdaq
- Market Cap
- TSHA 1.4B
- GABC 1.5B
- IPO Year
- TSHA 2020
- GABC N/A
- Fundamental
- Price
- TSHA $4.72
- GABC $38.21
- Analyst Decision
- TSHA Strong Buy
- GABC Hold
- Analyst Count
- TSHA 8
- GABC 3
- Target Price
- TSHA $9.63
- GABC $45.33
- AVG Volume (30 Days)
- TSHA 11.3M
- GABC 99.3K
- Earning Date
- TSHA 11-12-2025
- GABC 10-29-2025
- Dividend Yield
- TSHA N/A
- GABC 3.08%
- EPS Growth
- TSHA N/A
- GABC N/A
- EPS
- TSHA N/A
- GABC 2.62
- Revenue
- TSHA $8,098,000.00
- GABC $281,091,000.00
- Revenue This Year
- TSHA N/A
- GABC $46.34
- Revenue Next Year
- TSHA N/A
- GABC $6.11
- P/E Ratio
- TSHA N/A
- GABC $14.37
- Revenue Growth
- TSHA N/A
- GABC 13.87
- 52 Week Low
- TSHA $1.05
- GABC $32.75
- 52 Week High
- TSHA $5.51
- GABC $47.08
- Technical
- Relative Strength Index (RSI)
- TSHA 59.56
- GABC 43.12
- Support Level
- TSHA $4.80
- GABC $37.40
- Resistance Level
- TSHA $5.51
- GABC $39.49
- Average True Range (ATR)
- TSHA 0.44
- GABC 0.86
- MACD
- TSHA 0.04
- GABC -0.07
- Stochastic Oscillator
- TSHA 66.02
- GABC 43.23
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About GABC German American Bancorp Inc.
German American Bancorp Inc is a bank holding company. The lines of business include Retail and commercial banking business which involves attracting deposits from the general public and using those funds to originate consumer, commercial and agricultural, commercial and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services which involve providing trust, investment advisory, brokerage and retirement planning services to customers. Insurance operations include the offering of a full range of personal and corporate property and casualty insurance products.